{"id":742289,"date":"2013-11-02T09:00:00","date_gmt":"2013-11-02T09:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/"},"modified":"2023-03-22T00:04:32","modified_gmt":"2023-03-22T04:04:32","slug":"merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/","title":{"rendered":"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       Sustained virologic response at post-treatment follow-up week 12 (SVR        12) seen in 100 percent of patients to date in two of the three        combination arms studied     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      announced the presentation of interim data from the ongoing C-WORTHY<br \/>\n      Study, a Phase II clinical trial evaluating the efficacy and safety of<br \/>\n      an all-oral regimen combining once-daily MK-5172, an investigational<br \/>\n      hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an<br \/>\n      investigational HCV NS5A replication complex inhibitor, with or without<br \/>\n      twice-daily ribavirin, administered for 12 weeks to treatment-na\u00efve,<br \/>\n      non-cirrhotic patients with HCV genotype 1a and 1b infection. The<br \/>\n      interim data show that the administration of MK-5172 and MK-8742 in<br \/>\n      combination is associated with a sustained virologic response (lack of<br \/>\n      detectable and quantifiable HCV) 12 weeks following the end of study<br \/>\n      therapy (SVR12). Merck previously announced that the U.S. Food and Drug<br \/>\n      Administration (FDA) granted Breakthrough Therapy designation to<br \/>\n      MK-5172\/MK-8742 for treatment of chronic HCV infection.\n    <\/p>\n<p>\n      \u201cWe are encouraged by these preliminary data for the combination of<br \/>\n      MK-5172 and MK-8742,\u201d said, Dr. Eliav Barr, vice president, Infectious<br \/>\n      Diseases, Merck Research Laboratories. \u201cThese data provide further<br \/>\n      support that we can advance these candidates, which are currently in<br \/>\n      Phase IIB clinical development, into a broader evaluation in a diverse<br \/>\n      range of HCV patients.\u201d\n    <\/p>\n<p>\n      <b>C-WORTHY Study<\/b>\n    <\/p>\n<p>\n      In the C-WORTHY Study, 65 patients (45% male, 11% African American, and<br \/>\n      58% genotype 1a infection) were enrolled in one of three 12-week<br \/>\n      treatment arms (see TABLE). The ribavirin (RBV) arms were stratified by<br \/>\n      genotype 1a versus genotype 1b. The RBV-free arm included only genotype<br \/>\n      1b-infected patients. Virologic response was assessed each week during<br \/>\n      treatment and at 2, 4, 8, 12 and 24 weeks after the end of treatment.<br \/>\n      The primary efficacy endpoint of the trial was the proportion of<br \/>\n      patients who achieved sustained virologic response at post-treatment<br \/>\n      follow-up week 12 (SVR12).\n    <\/p>\n<p>\n      The primary analysis population was per protocol, including patients who<br \/>\n      did not have protocol violations and had received the correct study<br \/>\n      medications. A total of 58\/65 enrolled patients met these criteria (see<br \/>\n      TABLE).\n    <\/p>\n<p>\n      Of the seven patients who were not in the per-protocol population, four<br \/>\n      achieved SVR12 and three discontinued early for reasons other than<br \/>\n      adverse experiences or virologic failure.\n    <\/p>\n<p>\n      Among the entire study population of 65 patients, one patient (1.5%)<br \/>\n      experienced a relapse with detectable HCV RNA at follow-up week 4 and 12.\n    <\/p>\n<p>\n      <b>TABLE<\/b>\n    <\/p>\n<p>\n      <b>Primary Analysis Population: Per Protocol*<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>Arm<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>Regimen<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>N<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>GT1a \/ GT1b<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>SVR4<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>SVR12<\/b><sup><b>#<\/b><\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>1<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          MK-5172 (100 mg) + MK-8742 (20 mg) + ribavirin\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          22\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          76% \/ 24%\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          22\/22<\/p>\n<p class=\"bwcellpmargin\">\n            (100%)\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          21\/21<\/p>\n<p class=\"bwcellpmargin\">\n            (100%)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>2<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          MK-5172 (100 mg) + MK-8742 (50 mg) + ribavirin\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          24\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          70% \/ 30%\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          23\/24<\/p>\n<p class=\"bwcellpmargin\">\n            (96%)\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          23\/24<\/p>\n<p class=\"bwcellpmargin\">\n            (96%)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          <b>3<\/b>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          MK-5172 (100 mg) + MK-8742 (50 mg)\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          12\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% \/ 100%\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            12\/12<br \/>(100%)\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          11\/11<\/p>\n<p class=\"bwcellpmargin\">\n            (100%)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"6\">\n<p class=\"bwcellpmargin\">\n            * Seven Patients were excluded from the Per Protocol Population\n          <\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<ul>\n<li>\n              <i>4 patients received incorrect RBV doses (3 received &lt;50% of<br \/>\n              the prescribed dose:1 given RBV in the RBV-free arm); all<br \/>\n              achieved HCV-RNA &lt;25 IU\/mL at FU12<\/i>\n            <\/li>\n<li>\n              <i>3 patients discontinued early:1 patient at Day 3 (violated<br \/>\n              protocol inclusion criterion), and 2 patients at Day 22 and Day<br \/>\n              35 (withdrew consent \u2013 patients had undetectable HCV RNA at the<br \/>\n              time of discontinuation)<\/i>\n            <\/li>\n<\/ul>\n<p class=\"bwcellpmargin\">\n            <sup><i>#<\/i><\/sup><i>Two patients have not reached SVR12<\/i>\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The most frequently reported adverse events occurring in the study were<br \/>\n      fatigue (26%), headache (22%), nausea (18%), diarrhea (12%), dizziness<br \/>\n      (11%) and rash (11%). The incidence of anemia (&lt;10 mg\/dL hemoglobin) and<br \/>\n      elevated total bilirubin levels to 2 times the upper limit of normal was<br \/>\n      19 percent and 4 percent, respectively, in the RBV-containing arms<br \/>\n      (combined arms 1 and 2), and 0 percent and 0 percent, respectively, in<br \/>\n      the RBV-free arm. No grade 3 or 4 laboratory abnormalities were<br \/>\n      observed. There were eight cases of rash. Seven cases of rash were<br \/>\n      observed in the RBV-containing arms; half of these cases were attributed<br \/>\n      to RBV. The single case in the RBV-free arm was not study drug related<br \/>\n      and was mild in intensity. No early discontinuations due to drug-related<br \/>\n      adverse events were recorded.\n    <\/p>\n<p>\n      The C-WORTHY trial has been expanded to evaluate the safety and efficacy<br \/>\n      of MK-5172 and MK-8742, with or without RBV, in difficult-to-cure HCV<br \/>\n      genotype 1-infected patient populations. Approximately 400 additional<br \/>\n      HCV genotype 1-infected patients have been enrolled in this trial. The<br \/>\n      expanded C-WORTHY study is testing:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        8 week regimen of MK-5172\/MK-8742 + RBV in treatment na\u00efve<br \/>\n        non-cirrhotic patients\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        12 week regimen of MK-5172\/MK-8742 without RBV in treatment-na\u00efve<br \/>\n        non-cirrhotic patients\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        12 week regimens (MK-5172\/MK-8742 with or without RBV) among HIV<br \/>\n        co-infected patients\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        12 or 18 week regimens (MK-5172\/MK-8742 with or without RBV) in<br \/>\n        patients with cirrhosis\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        12 or 18 week regimens (MK-5172\/MK-8742 with or without RBV) in<br \/>\n        patients who had failed to respond to prior peginterferon and RBV<br \/>\n        therapy (\u201cnull responders\u201d).\n      <\/li>\n<\/ul>\n<p>\n      Details on the C-WORTHY Study, as well as additional phase II trials for<br \/>\n      MK-5172 and MK-8742, can be viewed on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01717326%3Fterm%3Dmk-5172%252C%2Bmk-8742%26rank%3D2&amp;esheet=50742546&amp;newsitemid=20131102005029&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=1&amp;md5=556869646c62460fd384babed8750afc\" rel=\"nofollow\">ClinicalTrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50742546&amp;newsitemid=20131102005029&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=06e49e89a8a39ebf0ce05c561e0df7d9\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter%2FMerck&amp;esheet=50742546&amp;newsitemid=20131102005029&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=7af5ded158958df4126fc2d81ba64f45\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50742546&amp;newsitemid=20131102005029&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=2c7c999f200da347c0b2f912153540bc\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50742546&amp;newsitemid=20131102005029&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=65281601c57058db239c66f24b4304ff\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50742546&amp;newsitemid=20131102005029&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=4bfcec4299f0dbfaec2ff323d4fde8a1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, (908) 423-5042<br \/>Sarra Herzog,        (908) 423-6154<br \/>or<br \/>Investor:<br \/>Carol Ferguson, (908) 423-4465<br \/>Justin        Holko, (908) 423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-na\u00efve, non-cirrhotic patients with HCV genotype 1a and 1b infection. The interim data show that the administration of MK-5172 and MK-8742 in combination is associated with a sustained virologic response (lack of detectable and quantifiable HCV) 12 weeks following the end of study therapy (SVR12). Merck previously announced that the U.S. Food and Drug<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742289","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-na\u00efve, non-cirrhotic patients with HCV genotype 1a and 1b infection. The interim data show that the administration of MK-5172 and MK-8742 in combination is associated with a sustained virologic response (lack of detectable and quantifiable HCV) 12 weeks following the end of study therapy (SVR12). Merck previously announced that the U.S. Food and Drug\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/\",\"name\":\"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2013-11-02T09:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Merck.com","og_description":"Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-na\u00efve, non-cirrhotic patients with HCV genotype 1a and 1b infection. The interim data show that the administration of MK-5172 and MK-8742 in combination is associated with a sustained virologic response (lack of detectable and quantifiable HCV) 12 weeks following the end of study therapy (SVR12). Merck previously announced that the U.S. Food and Drug","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:32+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/","name":"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2013-11-02T09:00:00+00:00","dateModified":"2023-03-22T04:04:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131102005029r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-of-investigational-combination-of-hcv-therapies-mk-5172-and-mk-8742-at-the-2013-american-association-for-the-study-of-liver-diseases-aasld-ann\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"68810b65-c765-40f6-815a-0ec7d4ce0a88","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Presentation-of-Interim-Data-from-Study-of-Investigational-Combination-of-HCV-Therapies-MK-5172-and-MK-8742-at-the-20-SN790.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742289\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742289"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}